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Abstract
Objectives To evaluate the safety and efficacy of a filter
embolic protection device (FEPD) in endovascular inter-
ventions of the femoropopliteal arteries.
Methods Patients who underwent endovascular interven-
tions of the femoropopliteal arteries between 2008 and
2016 and in whom the SpiderFXTM FEPD was applied
were included in this retrospective study. Clinical and
angiographic characteristics, filter macroembolization
(FME), device-related complications, distal embolization,
as well as the early clinical and hemodynamic outcome,
were assessed. Potential risk factors for FME were evalu-
ated by multivariate analysis.
Results A total of 244 cases were identified (203 patients,
claudication 60.4%, critical limb ischaemia 39.6%, mean
lesion length 13.2 ± 12.9 cm, complete occlusions in
72.7%). Balloon angioplasty ± stenting (BAP), directional
atherectomy ± balloon angioplasty ± stenting (DA) and
rotational thrombectomy ± balloon angioplasty ± stenting
(RT) were performed in 141, 61 and 42 cases, respectively.
FEPD placement and retrieval were successful in all but
one case each. Permanent filter-related vessel damage was
not observed. The rate of FME was 37.3% (BAP 36.2%,
DA 32.8%, RT 47.7%). Risk factors for FME in the BAP-
and DA-group were total occlusion, lesion length[19 cm,
visible thrombus and diabetes mellitus. The distal
embolization rate despite filter protection was 4.1 % (BAP
4.9%, DA 1.6%, RT 4.8%) and was higher in cases with
FME compared with those without FME (8.7% vs. 1.5%,
p = 0.02).
Conclusion The Spider FXTM device is safe and effective
in capturing embolic debris during femoropopliteal inter-
ventions. A residual risk of peripheral embolization
remains.
Level of Evidence III, Cohort study
Keywords Peripheral arterial disease  Percutaneous
transluminal angioplasty  Atherectomy 
Thrombectomy  Embolization  Filter
Introduction
Peripheral embolization is a well-recognized, potentially
limb threatening complication of lower extremity
endovascular procedures, resulting in clinically significant
perfusion impairment at the cruropedal level in 1.6 to 4%
of patients, with higher numbers reported in the treatment
of acute thrombotic lesions (up to 24%) [1, 2]. Local
pharmacological or mechanical treatment of distal
embolization aims to restore distal perfusion but is asso-
ciated with longer intervention times, increased radiation
exposure and repeat interventions [2, 3]. Filter embolic
protection devices (FEPD) have been shown to effectively
capture emboli during lower extremity endovascular
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procedures [4–7]. However, data regarding the rational use
of FEPD in lower extremity endovascular procedures are
scarce and mainly limited to directional atherectomy [7, 8].
We sought to evaluate the procedural safety and efficacy
of a FEPD in a large contemporary cohort of patients with
acute, subacute and chronic obstructions of the femor-
opopliteal arteries, who either underwent balloon angio-
plasty ± stenting (BAP), directional
atherectomy ± balloon angioplasty ± stenting (DA) or
rotational thrombectomy ± balloon angioplasty ± stent-
ing (RT). We further aimed to determine potential pre-
dictors of peri-procedural filter macroembolization (FME).
Patients and Methods
Study Design and Clinical Assessment
The study protocol followed the principles of the Decla-
ration of Helsinki. Patients who underwent endovascular
interventions of the femoropopliteal arteries (and addi-
tionally of the iliac inflow and the crural outflow, if
required) between 2008 and 2016 were retrospectively
identified. Patients aged C 18 years suffering from symp-
tomatic peripheral arterial disease Rutherford stage 2–6
were eligible for study inclusion, provided that the target
lesion was successfully crossed by a guidewire.
Clinical data (symptom duration, cardiovascular
comorbidities, current medication and previous revascu-
larization procedures) were obtained from the medical
records. Laboratory values as well as pre- and post-inter-
ventional hemodynamic parameters (systolic ankle pres-
sures, ankle brachial index and segmental pulse volume
recordings of the forefoot) were recorded.
Endovascular Procedures
All procedures were performed by a single, experienced
interventional radiologist (M.T.). The endovascular pro-
cedures were carried out using 6–8F sheaths (antegrade
access or retrograde access with crossover-manoeuvre, as
appropriate) and after intraarterial administration of
5.000IU. of heparin.
The choice of a single revascularization technique or a
combination of more than one technique was at the dis-
cretion of the operator, based on symptom duration and
angiographic appearance. In general, DA was performed in
patients with chronic symptoms resulting from arte-
riosclerotic lesions (mainly stenoses), whereas RT was
applied in (sub-)acute occlusions of native arteries and
prosthetic bypass grafts with high clinical suspicion of
thrombotic material. BAP was used for treatment of both
chronic arteriosclerotic lesions and (sub-)acute occlusions.
DA and RT procedures all were performed under manda-
tory filter protection. In BAP procedures, utilization of the
FEPD was indicated when, based on clinical information
(e.g. symptom duration, previous revascularization) and
angiographic appearance (e.g. visible thrombus, flush
occlusion of a native artery or a bypass graft), an increased
periinterventional embolization risk was anticipated.
Standard balloon catheters were used for BAP. DA was
carried out with devices of the HawkTM-family (Medtronic
Vascular, Santa Rosa, CA, USA). RT was carried out with
RotarexTM-catheter systems (Straub Medical AG, Wangs,
Switzerland). DA and RT were followed by adjunctive
BAP, if necessary. If required (residual stenosis [ 30%,
flow limiting dissection), adjunctive stenting with self-ex-
panding nitinol stents (open-cell design) of various manu-
facturers was performed. Stent implantation was preceded
by lesion preparation in all cases. In some acute and sub-
acute thromboembolic occlusions, aspiration thrombec-
tomy and/or local thrombolysis was applied in addition to
the above-mentioned recanalization procedures.
Following lesion crossing with a 0.018 V-18TM Con-
trolWire (Boston Scientific, Malborough, MA, USA) and
prior to revascularization, the SpiderFXTM (EV3, Mans-
field, MA, USA) was inserted. The filter basket (size 3 to 7
mm, chosen according to the diameter of the vessel lumen
as determined by digital subtraction angiography) was
deployed at least 2 cm below the target lesion either in a
popliteal or, in case of single vessel crural run-off, in a
below-the-knee vessel segment. After release of the FEPD,
digital subtraction angiography images were obtained in
two projections in order to confirm adequate contact of the
FEPD to the vessel wall. After completed revasculariza-
tion, the FEPD was retrieved using the manufacturer-pro-
vided capturing catheter. Final completion angiography of
the treated lower extremity was performed in order to
document technical success and to assess distal run-off
with regard to peripheral embolization.
Post-interventional medical treatment consisted of dual
antiplatelet therapy with aspirin and clopidogrel for three to
six months, with the loading dose of clopidogrel (300 mg)
given immediately after the procedure. In patients with an
indication for oral anticoagulation (e.g. infrainguinal
venous bypass, atrial fibrillation), aspirin was combined
with oral anticoagulants at therapeutic doses instead of
clopidogrel.
Evaluation of Procedural Parameters
An experienced interventional radiologist (M.T.) reviewed
the digital subtraction angiography sequences. Lesion
characteristics (target vessel diameter, lesion length, grade
of calcification, visible thrombus, number of patent distal
run-off vessels in the index angiography and the final
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angiography) were analysed according to a predefined
protocol. Peri-procedural FEPD-related complications
were recorded, including problems with filter management,
filter-induced local vasospasm and permanent filter-related
permanent vessel damage.
Debris within the filter was classified using a modified
semiquantitative scoring system based on the appearance
of the filter basket during final magnified angiography, as
follows: (0) no visible material; (1) sludge with partial
occlusion of filter meshes or single debris particles (2)
macro-debris filling less than one-third of the filter; (3)
macro-debris filling more than one-third of the filter; (4)
completely filled filter basket (Fig. 1) [9]. Debris within the
filter C grade 2 was considered to be FME of potential
clinical relevance.
Outcome Parameters
The following outcome parameters were assessed:
- Successful filter management: placement and retrieval
of the FEPD without complications.
- Permanent filter-related damage: dissection, stenosis/
occlusion, perforation considered to be caused by the filter
basket/filter wire.
- Technically successful revascularization: restoration of
a regular blood flow at the lesion level with residual
stenosis \ 30% and patent crural run-off (at least one
artery).
- Hemodynamic improvement: increase in ankle bra-
chial index [ 0.15 and/or significant improvement of
forefoot pulse volume recordings by semiquantitative
assessment [10].
- Peripheral embolization: occurrence of a new angio-
graphic filling defect in a tibial, fibular or pedal artery
observed during the procedure or at final completion
angiography.
- FME of potential clinical significance: debris within
the filter C grade 2 was considered to be FME of potential
clinical relevance, given its potential to occlude a tibial or
fibular artery.
Statistical Analysis
Statistical analysis was performed with the R software for
statistical computing (R Development Core Team, Vienna,
Austria). Results for categorical variables are presented as
absolute numbers/percentages, and continuous variables
are displayed as mean ± standard deviation. For univariate
analysis, Fisher’s exact test and Wilcoxon’s rank sum test
were applied. Correction for multiple testing was done
using the Bonferroni method. To identify independent
predictors of FME, multiple logistic regression models
were calculated. Finally, decision tree analysis was per-




The main clinical and angiographic characteristics of the
244 included cases (203 patients) are summarized in
Table 1. Briefly, the mean age of the cohort was
71.4 ± 10.9 years, and 46.1% were women. Indication for
intervention was claudication (Rutherford categories 2 and
3) in 60.4% and critical limb ischaemia (Rutherford cate-
gories 4–6) in 39.6%. Acute symptoms lasting less than
14 days and subacute or chronic symptoms ([ 14 days)
were present in roughly half of the patients, respectively
(53.5 vs. 46.5%). Mean lesion length was 13.2 ± 12.9 cm,
and total occlusions were present in 72.7% of cases.
Occlusions of femoropopliteal or femoro-distal bypasses
Fig. 1 Angiographic examples of different grades of embolic debris
captured in the filter basket. 0, no visible material (A); 1, sludge with
partial occlusion of filter meshes or single debris particles (B); 2,
macro-debris filling less than one-third of the filter (C); 3, macro-
debris filling more than one-third of the filter (D); 4, completely filled
filter basket (E)
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accounted for 15.2% of cases. A three-, two- and one-
vessel run-off were present in 18.9%, 36.9% and 40.1% of
cases, respectively. Ten patients (4.1%) had no patent
crural artery.
DA and RT were performed in 61 (25%) and 42 (17.2%)
patients, respectively. The remaining 141 patients under-
went BAP without any debulking procedure. Adjunctive
aspiration thrombectomy and/or local thrombolysis was
performed in 28.3 and 17.6% of cases, respectively.
Additional endovascular treatment of iliac artery inflow or
crural artery outflow was performed in 2.0 and 31.1% of
cases.
Of note, the rate of patients with acute symptoms was
higher in the groups treated by RT (71.4%) and BAP
(55.6%) compared with DA (29.8%). Correspondingly, the
rate of patients with total occlusions was substantially
higher in these groups (RT 40.5% vs. BAP 55.3% vs. DA
3.3%). Aspiration thrombectomy and/or thrombolysis was
performed more frequently in the RT-group (40.5%) and
BAP-group (55.3%) compared with the DA-group (3.3%).
FEPD-Related Outcome
Deployment of the FEPD was successful in all but one
case. This patient was consequently treated with unpro-
tected RT which was complicated by peripheral
embolization. In another single case, retrieval of the FEPD
was not possible due to an overfilled filter, necessitating
FEPD removal in conjunction with the introducing sheath
without further complications. Thus, the rate of successful
filter management was 99.2%.
Permanent filter-related vessel damage was not
observed. However, vasospasm at the filter site requiring
intraarterial spasmolysis with nitroglycerine occurred in 11
cases (4.5%), including seven cases with filters at the crural
level and four cases with filters at the popliteal level.
Procedural and Clinical Outcome
Technically successful revascularization was achieved in
96.7% of cases. The corresponding rate of post-procedural
hemodynamic improvement was 93.0%. Revascularization
failed in eight cases (3.3%), including two patients with
Table 1 Comparison of clinical
and lesion characteristics
between patients treated by
balloon angioplasty ± stenting
(BAP), directional
atherectomy ± balloon
angioplasty ± stenting (DA)
and rotational
thrombectomy ± balloon







Age, years 71.7 ± 10.9 71.6 ± 9.4 70.3 ± 12.9
Male sex (%) 56.3 60.7 35.7
Arterial hypertension, % 78.9 93.3 78.0
Diabetes mellitus, % 23.9 42.6 14.3
Current or former smoking, % 57.1 65.6 53.7
Dyslipidemia, % 63.4 73.3 47.6
Coronary heart disease, % 30.3 23.0 35.7
Cerebrovascular disease, % 16.9 23.0 19.0
Statin treatment, % 54.3 58.3 57.1
Antiplatelet therapy, % 69.7 80.3 78.6
Dual antiplatelet therapy, % 12.7 8.2 19.0
Symptom duration, days 61 ± 136 104 ± 162 16 ± 32
Acute symptoms\ 14 days, % 56.6 29.8 71.4
Critical limb ischaemia, % 42.2 31.2 42.9
ABI 0.54 ± 0.39 0.66 ± 0.29 0.28 ± 0.25
Total occlusions, % 78.9 39.3 100
Recurrent lesions, % 37.3 54.1 71.4
Lesion length, cm 13.5 ± 12.6 11.2 ± 11.4 15 ± 15.6
Visible thrombus, % 22.7 19.7 33.3
Moderate/severe calcification, % 31.2 37.7 45.2
Distal run-off B 1 vessel 47.6 36.1 45.3
Adjunctive stenting, % 66.2 19.7 38.1
FME, % 36.2 32.8 47.7
Distal embolization, % 4.9 1.6 4.8
Continuous data are given as means ± standard deviation; categorical data are given as counts (percentage).
FME, filter macroembolization; ABI, ankle brachial index.
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primary technical failure and one patient in whom perfo-
ration of the popliteal artery following RT required urgent
surgical revascularization. Five patients experienced early
re-occlusions of the treated vessel segment within 24 hours
of the procedure.
Despite filter protection, peripheral embolization distal
to the FEDP occurred in ten cases (4.1%; BAP n = 7; RT
n = 2; DA n = 1), including nine total occlusions. The
mean symptom duration in these patients was 80 days
(range 4–365 days; four cases with acute symptoms
\ 14 days), and mean lesion length was 17.2 ± 16.4 cm
(range 8–42 cm). In five of these cases, aspiration
thrombectomy was attempted prior to filter placement. In
eight of the ten cases with peripheral embolization distal to
the FEDP, macroemboli were also found in the filter bas-
ket. Treatment consisting of aspiration thrombectomy
(n = 3) and/or thrombolysis (n = 8) was successful in nine
of the ten cases. After the procedure, hemodynamic
improvement was documented in all ten cases. Within a
mean follow-up time of 2.8 ? 2.9 years, freedom from
target lesion revascularization was documented in only two
of these ten cases. Eight re-occlusions occurred after a
mean of 0.9 ± 1.4 years, prompting revascularization
procedures in six patients (two of whom required bypass
surgery). One patient subsequently underwent lower limb
amputation.
Risk Factors for FME
Overall, peri-procedural FME considered to be of potential
clinical significance (C grade 2) occurred in 37.3% of
cases. FME was more common in patients who underwent
RT compared with DA and BAP (47.7% vs. 36.2% vs.
32.8%). Peripheral embolization distal to the FEPD was
documented in 4.1% of all patients and was significantly
more common in cases with FME compared with those
without FME (8.7% vs. 1.5%, p = 0.02).
Given the excessive risk of FME associated with RT,
further analysis evaluating risk factors for peri-procedural
embolism was restricted to the groups with DA and BAP
only. Results of the univariate analysis are listed in Table 2.
There was a trend towards a higher FME rate in cases with
critical limb ischaemia compared with cases with claudi-
cation, but a significant difference between patients with
and without FME was only found for mean lesion length
(C grade 2: 15.5 ± 13 cm vs. B grade 1: 11.3 ± 11.6 cm,
p\ 0.01). Notably, there was a remarkable overlap
between lesion lengths in patients with and without FME
(Fig. 2). A marked increase in the rate of FME was seen in
lesions exceeding a length of 19 cm when compared with
lesions shorter than 19 cm (FME rate 51.6 vs. 30.8%,
p = 0.04).
Logistic regression analysis favoured a model including
the following variables: total occlusion, lesion length
[ 19 cm, visible thrombus, DA procedure and chronic
antiplatelet therapy. However, comparison between
patients with and without chronic antiplatelet therapy
showed significantly worse patient- and lesion-based risk
profiles in the 73.9% of patients who were under chronic
([ 14 days of treatment) antiplatelet therapy prior to the
procedure (significantly higher prevalence of coronary
artery disease and current smoking, longer mean lesion
length, higher rate of recurrent lesions; data not shown).
Therefore, the variable antiplatelet therapy was excluded
from the final model, which included the following
parameters: total occlusion, lesion length[ 19 cm, visible
thrombus, DA procedure and diabetes mellitus. There was
a significant interaction between visible thrombus and
diabetes mellitus, leading to a marked risk increase for
FME (83%) for this small subset of patients (19 patients,
7.9% of the overall study population) with both factors.
The model showed a substantial discriminatory value for
patients with high, intermediate and low embolization risk.
In the group of patients treated with BAP, the model
allowed exact identification of a low-risk group (em-
bolization risk\ 12%) and a high-risk group (embolization
risk[ 75%) (Fig. 3). These findings were underscored by
decision tree analysis which discriminated a subset of cases
at very low risk (stenosis without visible thrombus) from
subgroups with low to moderate risk (occlusions\ 19 cm
without visible thrombus) and high risk (occlusions
[ 19 cm, lesions with visible thrombus) of FME (Fig. 4).
Discussion
FEPD appeared to be safe and effective in capturing
embolic debris during complex endovascular interventions
of the femoropopliteal arteries (overall rate of FME of
37.6%). Distal embolization despite filter protection
occurred in 4.1% of cases. The comparatively high rates of
both FME and distal embolization are mainly
attributable to the cohort characteristics, with large pro-
portion of cases presenting with acute symptoms and/or
complete occlusions particularly in the groups treated by
BAP or RT (more than 50% of the cases).
RT of (sub-)acute femoropopliteal occlusions was
associated with a rate of FME approaching 50% and a
distal embolization rate of 4.8%. Data on the risk of FME
during mechanical thrombectomy procedures are scarce.
Not surprisingly, Karnabatidis et al. identified mechanical
thrombectomy procedures as independent risk factors of
FME [11]. In older studies, distal embolization rates
between 25 and 56% were reported with various mechan-
ical thrombectomy procedures [12]. Recently published,
Michael Czihal et al: Embolic protection in complex femoropopliteal interventions
123
large cohort studies showed distal embolization rates of 5.5
and 12.7% with RT [13, 14]. Altogether, these data support
the routine use of FEPD when performing RT of acute and
subacute femoropopliteal occlusions.
In previous DA series, the reported rates of FME varied
widely, ranging from 9 to 91% [4, 6–8]. In the Definitive
LE study, including almost 800 participants with chronic
limb ischaemia, distal protection was at the discretion of
the operator. Consequently, FEPD was used in only 20% of
patients during DA, and the distal embolization rate was
3.8% [15]. In the Definitive Ca?? study, distal emboliza-
tion occurred at a lower rate in three out of 111 patients
with chronic limb ischaemia (2.3% of the study cohort)
who underwent filter-protected DA [6]. In our study, the
distal embolization rate during filter-protected DA was
1.6%. Based on a large series (n = 508) with patients who
underwent femoropopliteal DA with utilization of a FEPD,
Krishnan et al. were the first to propose an algorithm for
the rational use of FEPD in DA procedures [8]. Their
model included chronic total occlusions, in-stent-resteno-
sis, thrombotic lesions, lesions[ 140 mm, calcified lesions
[ 40 mm and the number of run-off vessels.
The role of FEPD in the setting of BAP of femor-
opopliteal lesions is less well defined. In large series
without filter protection, the rates of clinical significant
distal embolization were between 1.6 and 2.4% [2, 3]. In
the subset of cases treated by FEPD-protected BAP in our
series, the rate of significant distal embolization was even
higher (4.9%). However, this does not implicate that FEPD
paradoxically increases the risk of distal embolization but
rather reflects the characteristics of our preselected cohort
with a very high proportion of patients with (sub-)acute and
long occlusions. Correspondingly, in our series, every third
patient exhibited FME after BAP. Müller-Hülsbeck et al.
found FME (filter basket filled[1/3) in three of 30 stenotic
lesions of the femoropopliteal arteries treated with BAP
[9]. In the PROTECT-registry, FME occurred in 27.6% of
subjects treated with BAP [4]. Mendes et al. observed
moderate to severe debris burden in 45% of filter baskets
during 87 femoropopliteal interventions (98% BAP) [2].
By contrast, Spiliopolus et al. in a recent study found
microdebris in all filters but no evidence of FME in 40
patients who underwent subintimal recanalization of
chronic femoropopliteal occlusions [5].
Table 2 Comparison of clinical
and lesion characteristics of
patients with and without filter
macroembolism (analysis
limited to patients treated by
BAP and DA; patients treated






Age, years 71.5 ± 9.8 71.7 ± 11.5 0.88
Male sex (%) 58.5 56.3 0.77
Arterial hypertension, % 80.8 87.3 0.33
Diabetes mellitus, % 26.0 36.6 0.15
Current or former smoking, % 59.5 70.5 0.69
Dyslipidemia, % 64.6 70.4 0.44
Coronary heart disease, % 27.5 29.6 0.75
Cerebrovascular disease, % 19.1 18.3 1.0
Statin treatment, % 51.2 62.9 0.14
Antiplatelet therapy, % 63.4 56.3 0.38
Dual antiplatelet therapy, % 11.5 11.0 1.0
Symptom duration, days 69 ± 151 79 ± 135 0.50
Acute symptoms\ 14 days, % 51 45.5 0.62
Critical limb ischaemia, % 35.1 45 0.07
ABI 0.6 ± 0.36 0.53 ± 0.37 0.16
Total occlusions, % 69.5 62.0 0.35
Recurrent lesions, % 41.2 45.1 0.35
Lesion length, cm 11.3 ± 11.6 15.5 ± 13 \ 0.01
Visible thrombus, % 18.3 28.2 0.11
Moderate/severe calcification, % 29 40.9 0.23
Distal run-off B 1 vessel 42 47.8 0.41
Adjunctive stenting, % 51.1 53.5 0.77
Distal embolization, % 1.5 8.7 0.02
Continuous data are given as means ± standard deviation; categorical data are given as counts (percentage).
FME, filter macroembolization; ABI, ankle brachial index.
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In our analysis, thrombotic and long lesions, as well as
chronic occlusions, appeared to be associated with a par-
ticularly increased risk of FME also in the subgroup of
patients with BAP, whereas other parameters such as
symptom duration, lesion calcification and number of run-
off vessels were not. Chronic total occlusions, lesion
length, as well as thrombus burden, were positively cor-
related with the amount of captured particles in the series
by Karnabitides et al. [11]. According to the available data,
the use of FEPD during BAP in lesions with visible
thrombus burden, as well as in patients with long occlu-
sions, may be advisable.
In patients with compromised crural run-off, FEPD may
be used even more liberally to avoid clinically relevant
outflow deterioration [13]. The potential role of a ‘‘mi-
crocirculatory injury’’, well recognized in percutaneous
coronary interventions in acute myocardial infarction, is
insufficiently understood in the context of femoropopliteal
interventions [5, 16]. However, the ubiquitous phe-
nomenon of clinically silent microembolization may be of
importance particularly in repeated procedures [5]. Given
their excellent safety profile, as documented for the Spi-
derFXTM in our study, it is worth discussing the utilization
of FEPD at least in subjects considered to be at high risk
for distal embolization or with a predicted poor outcome in
case of distal embolization.
However, the level of evidence regarding the rational
use of FEPD in peripheral interventions remains low and
the additional costs must be taken into account. A huge
discrepancy exists between high rates of FME and the
remarkable lower rate of clinically significant distal
embolism in unprotected procedures. Noteworthy, in our
study, the rate of distal embolization was significantly
higher in cases with FME than in those without (8.7 vs.
1.5%). A consensus definition of how to define ‘‘clinically
significant’’ FME does not exist. While some studies
Fig. 2 Overlapping distribution of cases with and without FME in relation to lesion length (A). Comparison of mean (± standard deviation)
lesion length between patients with and without FME (B)
Fig. 3: Prediction of cases without (B grade 1) and with (C grade 2)
FME by the final logistic regression model in the subset of patients
treated with BAP (n = 141)
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provided no clear definitions of FME [2, 6, 8] and some
studies graded FME by particle diameter [4, 7], we applied
a modified semiquantitative evaluation of the debris load in
filter baskets based on final angiography before filter
retrieval [9]. It must be noted that our definition is arbitrary
and not evidence-based. Thus, it still remains to be eval-
uated which mode of debris analysis is preferable within
clinical studies.
Our retrospective study has some limitations, mainly the
inhomogeneous patient cohort, performance of endovas-
cular procedures by a single operator who was involved in
analysis of procedural parameters and the lack of a core
laboratory analysis. The comparatively high rates of both
FME and distal embolization are mainly attributable to an
obvious selection bias, as stated above.
As most studies with large patient numbers relied on retro-
spective data with the inherent risk of bias [2, 8], and
prospective studies with mandatory FEPD use were mainly
performed in the setting ofDA [6, 7], evaluation of the potential
clinical benefit and of the cost-effectiveness of FEPD in the
setting of a properly designed, prospective, randomized, con-
trolled study is warranted. Risk algorithms as stated above
could be helpful in enriching the study population with patients
carrying a high peri-procedural embolization risk.
In summary, our study showed an excellent safety pro-
file and the ability of the SpiderFXTM to effectively capture
macro-debris during different types of femoropopliteal
interventions. A residual risk of distal embolization
remains, and the discrepancy between high rates of FME
and much lower rates of distal embolization in unprotected
cases represents an unsolved problem. Our results may
inform future research aiming at determining the clinical
benefit of FEPD in certain clinical scenarios of femor-
opopliteal interventions.
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